U.S. pharma large copyright scrapped two experimental weight loss drugs very last year—a when-day by day tablet, lotiglipron, due to elevated liver enzymes as well as a twice-day-to-day pill, danuglipron, as a result of robust Unwanted side effects—but CEO Albert Bourla has explained